Literature DB >> 29491336

[Dropped head syndrome as first manifestation of primary hyperparathyroid myopathy].

Kiyobumi Ota1, Sayo Koseki2, Kenji Ikegami3, Iichiroh Onishi4, Hiyoryuki Tomimitsu1, Shuzo Shintani1.   

Abstract

75 years old woman presented with 6-month history of progressive dropped head syndrome. Neurological examination revealed moderate weakness of flexor and extensor of neck and mild weakness of proximal appendicular muscles with normal deep tendon reflexes. The needle electromyography showed short duration and low amplitude motor unit potential. No fibrillation potentials or positive sharp waves were seen. Biopsy of deltoid muscle was normal. Laboratory studies showed elevated levels of serum calcium (11.8 mg/dl, upper limit of normal 10.1) and intact parathyroid hormone (104 pg/ml, upper limit of normal 65), and decreased level of serum phosphorus (2.3 mg/dl, lower limit of normal 2.7). Ultrasonography and enhanced computed tomography revealed a parathyroid tumor. The tumor was removed surgically. Pathological examination proved tumor to be parathyroid adenoma. Dropped head and weakness of muscles were dramatically improved within a week after the operation. Although hyperparathyroidism is a rare cause of dropped head syndrome, neurologists must recognize hyperparathyroidism as a treatable cause of dropped head syndrome.

Entities:  

Keywords:  dropped head syndrome; hyperparathyroidism; myopathy; parathyroid adenoma

Mesh:

Year:  2018        PMID: 29491336     DOI: 10.5692/clinicalneurol.cn-001125

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  2 in total

1.  Dropped head syndrome due to neuromuscular disorders: Clinical manifestation and evaluation.

Authors:  Ahmet Z Burakgazi; Perry K Richardson; Mohammad Abu-Rub
Journal:  Neurol Int       Date:  2019-06-19

2.  Normocalcemic Primary Hyperparathyroidism Presenting with Muscle Weakness and Body Pain.

Authors:  Izumi Mihashi; Kazuhiro Ishii; Yasuhiro Ogawa; Ayako Uchida; Hisato Hara; Akira Tamaoka
Journal:  Intern Med       Date:  2020-11-30       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.